Table 2.
Total treatment-related adverse effects in mccRCC patients
| Adverse events | Studies involved | Event/Total | % |
|---|---|---|---|
| Circulatory system AEs | |||
| Anemia | 7 | 599/713 | 84.01 |
| Hypertension | 3 | 87/132 | 65.91 |
| Thrombocytopenia | 1 | 13/50 | 26 |
| Edema | 5 | 92/581 | 15.83 |
| Decreased lymphocyte count | 1 | 4/55 | 7.27 |
| Decreased platelet count | 1 | 3/55 | 5.45 |
| Digestive system AEs | |||
| Dysgeusia | 1 | 25/50 | 50 |
| Nausea | 7 | 181/713 | 25.39 |
| Diarrhoea | 6 | 151/713 | 21.18 |
| Decreased appetite | 7 | 134/713 | 18.79 |
| Increased alanine aminotransferase | 6 | 111/683 | 16.25 |
| Increased aspartate aminotransferase | 6 | 104/683 | 15.23 |
| Vomiting | 3 | 64/477 | 13.42 |
| Constipation | 3 | 68/526 | 12.93 |
| Stomatitis | 2 | 23/422 | 5.45 |
| Endocrine system AEs | |||
| Hypophosphataemia | 2 | 29/102 | 28.43 |
| Hypothyroidism | 1 | 11/50 | 22 |
| Increased blood creatinine | 2 | 35/427 | 8.2 |
| Hemoglobin decreased | 2 | 12/154 | 7.79 |
| Hypertriglyceridemia | 1 | 14/372 | 3.76 |
| Increased blood alkaline phosphatase | 1 | 3/55 | 5.45 |
| Hypercalcemia | 1 | 2/55 | 3.64 |
| Hyperglycemia | 1 | 10/372 | 2.69 |
| Skin AEs | |||
| Palmar–plantar erythrodysesthesia | 2 | 51/102 | 50 |
| Pruritus | 3 | 35/526 | 6.65 |
| Rash | 1 | 17/372 | 4.57 |
| Nervous system AEs | |||
| Fatigue | 7 | 326/713 | 45.72 |
| Headache | 4 | 67/581 | 11.53 |
| Dizziness | 4 | 65/581 | 11.19 |
| Respiratory system AEs | |||
| Dyspnea | 4 | 87/526 | 16.54 |
| Cough | 4 | 41/581 | 7.06 |
| Pneumonitis | 2 | 6/427 | 1.41 |
| Locomotor system AEs | |||
| Arthralgia | 1 | 54/372 | 14.52 |
| Myalgia | 3 | 11/209 | 5.26 |
| Muscular weakness | 1 | 2/55 | 3.64 |
| Others AEs | |||
| Proteinuria | 2 | 36/85 | 42.35 |
| Weight decreased | 1 | 11/50 | 22 |
| Hypoxia | 4 | 105/526 | 19.96 |
| Back pain | 1 | 55/372 | 14.78 |
| Asthenia | 4 | 61/581 | 10.5 |
| Pyrexia | 1 | 22/372 | 5.91 |
| Increased weight | 2 | 7/133 | 5.26 |
| Flushing | 1 | 2/55 | 3.64 |
| Malaise | 1 | 2/55 | 3.64 |
Abbreviations AEs adverse effects, mccRCC advanced or metastatic clear cell renal cell carcinoma